| Asaf Danziger |
Asaf Danziger is currently the Chief Executive Officer & Director at NovoCure Ltd. since 2012. He is also the Co-Managing Director at NovoCure GmbH since 2012. Previously, he served as the Chief Executive Officer at Cybro Medical Ltd. from 1998 to 2002. He has also held positions as a Director at NanoPass Technologies Ltd. and ID-U Biometrics Ltd. Additionally, he served as a Communications & Electronics Officer in the Israel Defense Forces. Mr. Danziger obtained his undergraduate degree from Ben-Gurion University of the Negev. |
| William F. Doyle |
William F. Doyle founded WFD Ventures LLC in 2003, where he is working as Managing Director from 2003. Mr. Doyle also founded Durel Corp and Sequel Med Tech LLC, where he is working as Director. Mr. Doyle also currently works at Blink Health, Inc., as Executive Chairman, NovoCure Ltd., as Executive Chairman from 2016, Aspire Bariatrics, Inc., as Director, VisionScope Technologies LLC, as Director, ProKidney Corp., as Independent Director from 2022, Pershing Square Sohn Cancer Research Alliance, as Director, and Elanco Animal Health, Inc., as Independent Director from 2020. Mr. Doyle also formerly worked at ImaCor, Inc., as Chairman, Cordis Corp., as Director, Vision-Sciences, Inc., as Director, Revitas, Inc., as Director, ProterixBio, Inc., as Director, BionX Medical Technologies, Inc., as Director, Advanced Surgical Concepts Ltd., as Non-Executive Director, OptiNose, Inc., as Independent Director from 2010 to 2020, Johnson & Johnson Innovation - JJDC, Inc., as Director, Insight Venture Management LLC, as Managing Director, Medusind of Miami, Inc., as Director, Zoetis, Inc., as Independent Director from 2015 to 2016, Clozex Medical LLC, as Director, NanoPass Technologies Ltd., as Director, Optinose AS, as Director from 2004 to 2010, Angioslide Ltd., as Director, Andrew Technologies LLC, as Director, Inventure LLC, as Director, Minerva Neurosciences, Inc., as Lead Independent Director from 2018 to 2023, OptiNose US, Inc., as Director, Johnson & Johnson, as Vice President-Licensing & Acquisitions from 1994 to 1999, American Superconductor Corp., as Principal, McKinsey & Co., Inc., as Consultant, Cutlass Capital LLC, as Advisor, Pershing Square Capital Management LP, as Member-Investment Team from 2014 to 2016, and Biosense Webster, Inc., as President. Mr. Doyle received his undergraduate degree from Massachusetts Institute of Technology and Masters Business Admin degree from Harvard Business School. |
| Frank Leonard |
Frank Leonard is currently working as the Executive Vice President & President-Oncology at NovoCure Ltd. He started this position in 2010 and is still currently employed there. In terms of education, Mr. Leonard completed his undergraduate degree at Harvard University and his graduate degree at the London School of Economics & Political Science. |
| Ashley Cordova |
Ashley Cordova is currently working as the Chief Financial Officer at NovoCure Ltd. She started this position in 2020. Prior to her current role, she obtained an undergraduate degree from Furman University. She also holds an MBA from the University of South Carolina. |
| Nicolas Leupin |
Nicolas Leupin is currently the Chief Medical Officer at NovoCure Ltd. He previously held the same position at Molecular Partners AG from 2019 to 2023 and at argenx SE from 2016 to 2019. He was also a member of the Swiss Group for Clinical Research. Leupin holds an MBA from Jones International University and a doctorate from the University of Bern. |
| Michael Puri |
Michael Puri is currently the Chief Human Resources Officer at NovoCure Ltd. and also holds a position as Chief Human Resources Officer at Vifor Pharma Management AG. Previously, he worked as Senior Director-Global Talent Development at UCB SA from 2002 to 2010, and as VP-Europe Human Resources Division at Staples, Inc. from 2010 to 2013. He also served as Chief Human Resources Officer & Senior VP at Vifor Pharma AG and Global Head-Human Resources at GrandVision NV. Mr. Puri holds a graduate degree from Grenoble Ecole de Management and an undergraduate degree from the University of Nantes. |
| Uri Weinberg |
Uri Weinberg is currently the Chief Innovation Officer at NovoCure Ltd. He holds a doctorate degree from the Israel Institute of Technology. |
| William Bruke |
Currently, William Bruke is Chief Human Resources Officer at NovoCure Ltd.
He received an undergraduate degree from the University of Bridgeport. |
| Moshe Giladi |
Moshe Giladi is currently the Chief Science Officer at NovoCure Ltd. He has a graduate and doctorate degree from Tel-Aviv University. |
| Piet Hinoul |
Currently, Piet Hinoul holds the position of Senior Vice President & Head-Medical at NovoCure Ltd. |
| Wilhelmus C. M. Groenhuysen |
Wilhelmus C. M. Groenhuysen currently works at OptiNose, Inc., as Independent Director from 2017, NovoCure GmbH, as Co-Managing Director, and NovoCure Ltd., as Chief Operating Officer from 2020. Mr. Groenhuysen also formerly worked at Here Holding Corp., as Director, ChemGenex Pharmaceuticals Pty Ltd., as Director, Cephalon, Inc., as Chief Financial Officer & Executive Vice President from 2007 to 2011, and Philips Electronics North America Corp., as Chief Financial Officer & Senior Vice President. Mr. Groenhuysen received his graduate degree from Vrije Universiteit Amsterdam. |
| Kristin Stafford |
Kristin Stafford is an Independent Director at NovoCure Ltd. since 2023. She is also the Chief Accounting Officer & Senior Vice President at Royalty Pharma Plc since 2016. Previously, she worked as a Director-Capital Markets at Ernst & Young LLP (United Kingdom) and as an Auditor at Deloitte & Touche LLP. Ms. Stafford completed her undergraduate degree at Sonoma State University. |
| Timothy J. Scannell |
Timothy J. Scannell is currently serving as the Chairman at Synaptive Medical, Inc. He is also the Independent Chairman at Insulet Corp., Independent Director at EXACT Sciences Corp., Independent Director at NovoCure Ltd., Director at Collagen Matrix, Inc., Director at Cerebral Therapeutics, Inc., and Independent Director at Molekule Group, Inc. In his former positions, Mr. Scannell served as a Director at Entellus Medical, Inc., Independent Non-Executive Director at Renalytix Plc, Independent Director at AeroClean Technologies, Inc., President & Chief Operating Officer at Stryker Corp., President at Stryker Spine, and Vice President & General Manager at Stryker Biotech LLC. Mr. Scannell completed his undergraduate degree and received an MBA from the University of Notre Dame. |
| David T. Hung |
David T. Hung is the founder of Medivation, Inc. (2003), Medivation LLC (California) (1995), Nuvation Bio Operating Co., Inc. (2018), and Nuvation Bio, Inc. (2018). He is also the founder of Repharmation, Inc. Dr. Hung's current jobs include Independent Director at NovoCure Ltd. (2018-present), Director at Establishment Labs SA (2016-present), and Director at Auransa, Inc. (present). Dr. Hung's former jobs include President & Chief Executive Officer at Orion Acquisition Corp. II, President, Chief Executive Officer & Director at Pro-Duct Health, Inc. (1998-2001), President, Chief Executive Officer & Director at Medivation Neurology LLC (2003-2016), Chief Executive Officer & Director at Sio Gene Therapies, Inc. (2017-2018), Chief Executive Officer & Director at Axovant Sciences, Inc. (2017-2018), Director at Agilvax, Inc., Director at Solbec Pharmaceuticals Ltd., Independent Director at Opexa Therapeutics, Inc. (2006-2011), Director at NKT Therapeutics, Inc., Director at Roivant Sciences GmbH, Independent Director at Establishment Labs Holdings, Inc. (2016-2021), and Independent Director at ARYA Sciences Acquisition Corp. Dr. Hung's education includes an undergraduate degree from Harvard College and a doctorate degree from UCSF School of Medicine. |
| Jeryl Lynn Hilleman |
Jeryl Lynn Hilleman is currently the Chairman at Omada Health, Inc. She is also an Independent Director at SI-BONE, Inc., NovoCure Ltd., Minerva Neurosciences, Inc., and HilleVax, Inc. Additionally, she is a Member of the Henry Crown Fellowship Program, a Trustee at GeoHazards International, and a Member of the Aspen Global Leadership Network. In her former positions, Ms. Hilleman served as an Independent Director at XenoPort, Inc. from 2004 to 2018. She was also a Director at Talis Biomedical Corp. from 2021 to 2022. She held the position of Chief Financial Officer & Vice President-Finance at Geron Corp. from 1992 to 1997 and Chief Financial Officer & Executive Vice President at Symyx Technologies, Inc. from 1997 to 2007. She served as the Chief Financial Officer at Intersect ENT, Inc. from 2014 to 2019 and Amyris, Inc. from 2008 to 2012. She was the CFO, Secretary, CAO & Head-Investor Relations at OCERA Therapeutics LLC from 2013 to 2014. Additionally, she held the position of Chief Financial Officer & Vice President-Finance at Cytel Corp. from 1987 to 1999. Ms. Hilleman completed her undergraduate studies at Brown University and earned an MBA from The Wharton School of the University of Pennsylvania. |
| Martin J. Madden |
Martin J. Madden is an Independent Director at NovoCure Ltd. and Microbot Medical, Inc. He was also an Independent Director at TSO3, Inc. from 2018 to 2019. He served as Vice President-Medical Device R&D Transformation at Johnson & Johnson from 2016 to 2017 and Vice President-Research & Development at DePuy Synthes, Inc. from 1986 to 2017. He was also a Director at Mardil, Inc. Mr. Madden holds a graduate degree from Carnegie Mellon University, an MBA from The Trustees of Columbia University in The City of New York, and an undergraduate degree from the University of Dayton. |
| William Anthony Vernon |
William Anthony Vernon is currently an Independent Director at McCormick & Co., Inc., a Director at WhiteWave Foods, Inc., a Lead Independent Director at NovoCure Ltd., a Director at McCormick Foods Australia Pty Ltd., a Director at CMR Surgical Ltd., a Director at The Fynder Group, Inc., a Director at Nuvation Bio Operating Co., Inc., an Independent Director at Nuvation Bio, Inc., and an Advisor at Intrinsic Capital Partners. In the past, Mr. Vernon served as the President & Chief Executive Officer at Centocor, Inc., the President, Chief Executive Officer & Executive VP at Kraft Foods North America, Inc., the Group Chairman at DePuy, Inc., an Independent Director at Disc Dynamics, Inc., an Independent Director at Intersect ENT, Inc., an Independent Director at Zeo, Inc., a Director at Kraft Foods Group, Inc., a Director at Medivation, Inc., an Independent Director at CBR Systems, Inc., an Independent Director at Danone US, Inc., an Independent Director at ULURU, Inc., a Director at Philadelphia Youth Organization, a Director at Danone Medical Nutrition North America, Inc., a Director at Roivant Sciences GmbH, a Director at Sio Gene Therapies, Inc., a Director at Axovant Sciences, Inc., and the President at Johnson & Johnson. He was also a Partner at Ripplewood Investments LLC, an Executive Vice President at Mondelez International, Inc., the President at McNeil Consumer Healthcare (Canada), the President at McNeil Nutritionals LLC, the President at Johnson & Johnson-Merck Consumer Pharmaceuticals Co., and the President at McNeil Consumer Products Co.Mr. Vernon obtained an undergraduate degree from Lawrence University and an MBA from Kellogg School of Management. |
| Allyson J. Ocean |
Allyson J. Ocean is an Independent Director at NovoCure Ltd. He obtained an undergraduate degree from Tufts University and a doctorate from Tufts University School of Medicine. |
